Results 21 to 30 of about 1,043 (146)

Current Perspectives on Letermovir and Maribavir for the Management of Cytomegalovirus Infection in Solid Organ Transplant Recipients

Drug Design, Development and Therapy
Raymund R Razonable1,2 1Division of Public Health, Infectious Diseases and Occupational Medicine, Mayo Clinic, Rochester, MN, USA; 2William J von Liebig Center for Transplantation and Clinical Regeneration, Mayo Clinic, Rochester, MN, USACorrespondence ...
Raymund R Razonable
exaly   +2 more sources

Revisiting cytomegalovirus in pediatric allogeneic hematopoietic stem cell transplant recipients: current strategies for prevention and management in the letermovir era [PDF]

Frontiers in Pediatrics
CMV infection remains the most common clinically significant infection in pediatric allogeneic hematopoietic stem cell (HCT) recipients, with seropositive recipients of transplants from seronegative donors at the highest risk for complications. In recent
Lisa Hiskey, Diego R. Hijano, Diego R. Hijano, Ramia Zakhour   +3 more
doaj   +2 more sources

Advancements in Cytomegalovirus Management Among Solid Organ Transplant Recipients: Insights From the ESOT CMV Workshop 2023 [PDF]

Transplant International
Cytomegalovirus (CMV) infection poses significant challenges in solid organ transplant (SOT) recipients, impacting graft outcomes, morbidity, and in some cases survival.
Luca Toti, Nassim Kamar, Sophie Alain, Sophie Alain, Oriol Manuel, Nikolina Basic-Jukic, Paolo Antonio Grossi, Hannah Kaminski, Paolo Solidoro, Luciano Potena   +9 more
doaj   +2 more sources

The Troll Is Weakened but Not yet Defeated: An Update on Cytomegalovirus Management in Transplantation From the International CMV Symposium 2025. [PDF]

Transpl Infect Dis
This review synthesizes discussions from the 2025 International CMV Symposium on translating three recently updated international guidelines into clinical practice across solid organ and hematopoietic stem cell transplantation, highlighting advances in risk‐stratified prevention, emerging therapies, immune monitoring, and persistent implementation ...
Kotton CN, Sester M, Torre-Cisneros J, International CMV Symposium Faculty.   +3 more
europepmc   +2 more sources

Human Cytomegalovirus Infection in Haematopoietic Stem Cell Transplant Recipients and CAR-T Cell Recipients-PART 2: Antiviral Therapy and Virus-Specific T Cell Therapy for HCMV in Allo-HSCT. [PDF]

Rev Med Virol
ABSTRACT Human cytomegalovirus (HCMV) reactivation is a common and significant complication after allogeneic haematopoietic stem cell transplantation (allo‐HSCT), causing potentially life‐threatening disease. Antiviral therapy approaches for HCMV are often limited by toxicities and the risk of developing antiviral drug resistance.
Sutrave G, Yong MK, Kaplan D, Gottlieb DJ, Abendroth A, Slobedman B, Blyth E, Stern L.   +7 more
europepmc   +2 more sources

Maribavir

American Journal of Health-System Pharmacy, 2022
Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing ...
Terri L. Levien, Danial E. Baker
openaire   +4 more sources

Cytomegalovirus and Crohn’s disease as competing causes of small bowel inflammation after double-lung transplantation [PDF]

European Clinical Respiratory Journal
Background Cytomegalovirus (CMV) infection remains a significant cause of morbidity following solid organ transplantation, most frequently affecting the gastrointestinal tract.
Julie Hansen Niklassen, Christian Lodberg Hvas, Kristian Schønning, Kasper Sommerlund Moestrup, Marie Helleberg, Michael Perch, Elisabeth Bendstrup   +6 more
doaj   +2 more sources

Real-World Use of Letermovir and Maribavir for CMV Prophylaxis and Treatment in Solid Organ Transplant Recipients: Clinical Outcomes and Resistance Patterns From a Dual-Center Cohort. [PDF]

Pharmacotherapy
ABSTRACT Background Cytomegalovirus (CMV) is a major opportunistic infection in solid organ transplant (SOT) recipients. Although valganciclovir is first‐line for CMV treatment, its use may be limited by resistance and myelotoxicity. Letermovir (LET) and maribavir (MBV) are increasingly used as alternative therapies, though real‐world outcomes remain ...
Xu MT, Wright A, Mah A, Matic N, Lowe C, Hong C, Belga S, Tsai WP.   +7 more
europepmc   +2 more sources

Population pharmacokinetic modeling and simulation of maribavir to support dose selection and regulatory approval in adolescents with posttransplant refractory cytomegalovirus

CPT: Pharmacometrics & Systems Pharmacology, 2023
Maribavir was approved by the US Food and Drug Administration for the treatment of patients aged ≥12 years and weighing ≥35 kg with posttransplant cytomegalovirus infection/disease refractory (with/without resistance) to valganciclovir, ganciclovir ...
Kefeng Sun, Siobhan Hayes, Colm Farrell, Ivy H. Song   +3 more
doaj   +1 more source

New Treatment Options for Refractory/Resistant CMV Infection

Transplant International, 2023
Despite advances in monitoring and treatment, cytomegalovirus (CMV) infections remain one of the most common complications after solid organ transplantation (SOT).
Carla Simone Walti, Nina Khanna, Robin K. Avery, Ilkka Helanterä   +3 more
doaj   +1 more source